Viral Vector Manufacturing Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI3891
Viral Vector Manufacturing Market size is expected to grow significantly from 2019 to 2025.
Increasing adoption of adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, and retroviral vectors among others accelerates the viral vector manufacturing market growth. The production technology of adenoviral vectors is based on simple infection of producer cells by using serum-free media. Moreover, production of oncolytic adenoviral vectors have been used in a high cell density perfusion process at a 70L pilot scale for generating vector titers. Above-mentioned applications boosts the business growth. Use of such vectors in research institutes and several biotech companies to deliver genetic material into the cells should foster the viral vector manufacturing industry growth.
Viral vectors have been employed for the treatment of various diseases including cardiovascular, metabolic, hematologic, infectious diseases and different type of cancer. The above-mentioned factors proves beneficial for the viral vector manufacturing market growth. Furthermore, recent development in the area of immunotherapy has provided both therapeutic and preventive approaches that further accelerates the demand for viral vectors. Ample amount of preclinical studies have demonstrated prophylactic and therapeutic efficacy in animal models and also in clinical trials. Several such advantages related to viral vectors fosters the viral vector manufacturing market growth. However, high cost associated with gene therapy should hinder the viral vector manufacturing business growth.
Retroviral vectors segment is anticipated to witness lucrative growth over the analysis period. Ability of these vectors to deliver stable producer cell lines that constitutively produce viral vectors augments the segmental growth. Retroviral vectors are widely used as it can be cultivated in serum-free media in suspension culture that further propels the segment growth.
Infectious diseases segment will grow considerably during the analysis timeframe owing to rising prevalence of diseases globally. Focus of manufacturers on manufacturing viral vectors to treat several other diseases to provide effective health conditions accelerates the segmental growth.
Gene therapy segment will witness substantial growth during the forecast timeframe. Increasing prevalence of cancer including cervix uteri, colorectum, lung and breast cancer augments the gene therapy market growth. Rising number of cancer cases augments the demand for gene therapy for effective patient care and several gene therapy techniques in hospitals will foster the segmental growth.
Research institutes segment is projected to show substantial growth during the forthcoming years. Viral vectors are extensively used in research institutes for carrying out several procedures. Continuous focus of researchers to manufacture effective viral vector for treating different health disorders should augment the segmental growth.
North America viral vector manufacturing industry will account for substantial revenue share by 2025 owing to increasing awareness among population. High adoption rate for such therapies in this region and increasing prevalence of chronic disorders fosters the business growth.
Prominent industry players operating in viral vector manufacturing market include Fujifilm Diosynth Biotechnologies, Thermo fisher Scientific, Sanofi, Oxford BioMedica, and Merck. Notable market players operating in this business adopt numerous in-organic strategies to compete in the market over other players should boost the industry growth. For instance, in April 2018, GE Healthcare launched run factor in a box for rapid production of virus-based therapies. This has enhanced company’s presence in virus-based therapies.
Viral Vector Manufacturing Market By Type, 2014-2025 (USD Million)
- Adenoviral vectors
- Adeno-associated viral vectors
- Lentiviral vectors
- Retroviral vectors
Viral Vector Manufacturing Market By Disease, 2014-2025 (USD Million)
- Genetic disorders
- Infectious diseases
Viral Vector Manufacturing Market By Application, 2014-2025 (USD Million)
- Gene therapy
Viral Vector Manufacturing Market By End-user, 2014-2025 (USD Million)
- Research institutes
- Pharma and biotech companies
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Cobra Biologics
- Fujifilm Diosynth Biotechnologies
- Merck KGaA
- Kaneka Corporation
- Novasep Inc.
- Oxford BioMedica Plc.
- Sanofi SA
- Spark Therapeutics Inc.
- Thermo Fisher Scientific
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.